Founded in 2017 by Dr Nicola Shepherd, Bellows Consulting operates in the biomedical translational space, assisting clients in moving their projects closer to the market.
The range of services available include strategic advice on translation of technologies from the basic science environment into the clinic and towards the market; project oversight and strategy (Advisory Boards and Project Steering Groups); peer review including assistance in positioning applications for funding; establishing and managing funding schemes; and competitor analysis and due diligence including prior art searching. More detail can be found on the Services page.
Director, Nicola Shepherd
Nicola is the Founder and Director of Bellows Consulting. Most recently she was a senior member of the Innovations Division at the Wellcome Trust where she had worked for ten years. At Wellcome she was responsible for the establishment, management and oversight of the Translation Fund, a £30M a year investment into new product development covering therapeutics, vaccines, diagnostics, medical devices and regenerative medicine over a range of clinical indications.
During her time at Wellcome, Nicola has been involved in a broad array of translational activities including: assessment and triaging of translational project applications; contributing to and designing project strategy; licensing of project IP, and securing venture capital or other external investment. She has also negotiated a considerable number of agreements for Wellcome including Convertible Loans, Funding Agreements, Confidentiality Disclosure, Material Transfer and consent to exploitation of Intellectual Property.
Working closely with project teams, from academic, not-for-profit and commercial organisations, she has provided critical guidance and oversight in steering over 40 funded programmes from basic research towards or into the clinic.
Previously Nicola held positions at AstraZeneca in Late Stage Development and Manufacturing; at Global Prior Art based in Boston (US) carrying out competitor analysis, due diligence and prior art searching; and Brown University carrying out post-doctoral research into complex formulations.
She is a Member of the CARB-X Advisory Board (http://www.carb-x.org/), a public-private partnership valued at $350M over five years to tackle antibiotic resistance (Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator), a reviewer for Innovate UK and was previously on the External panel for the Alzheimer’s Drug Discovery Foundation (see Nature Reviews Drug Discovery 11, 833-846 (November 2012) | doi:10.1038/nrd3869).